Xeris Biopharma Holdings, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 44.39 million compared to USD 33.14 million a year ago. Net loss was USD 13.39 million compared to USD 12.93 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago.
For the full year, revenue was USD 163.91 million compared to USD 110.25 million a year ago. Net loss was USD 62.26 million compared to USD 94.66 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.7 a year ago.